The Latest Analyst Ratings For GoodRx Holdings
Portfolio Pulse from Benzinga Insights
GoodRx Holdings (NASDAQ:GDRX) received mixed analyst ratings with an updated average 12-month price target of $8.36, reflecting an 18.58% increase from the previous target. The company shows a positive revenue trend with a growth rate of 6.81% as of December 31, 2023, but lags behind industry peers. Its financial strength is highlighted by an exceptional net margin of -13.16% and a low debt-to-equity ratio of 0.93.
March 25, 2024 | 4:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GoodRx Holdings received mixed analyst ratings, with an updated average 12-month price target of $8.36, indicating a positive outlook. The company's financial performance shows a positive revenue trend but lags behind industry peers.
The mixed analyst ratings with a higher average price target suggest a cautiously optimistic outlook for GoodRx Holdings. The positive revenue trend and strong financial metrics like net margin and low debt-to-equity ratio support a potential short-term positive impact on GDRX's stock price. However, the lag in revenue growth compared to industry peers might temper the enthusiasm slightly.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100